Hundreds of Jewish students at Columbia University just published one of the most incredible student letters I have ever read.

It's not only magnificently written, but it also clearly articulates their experiences on campus for the past six months.

Their letter tells the story of

A lot about anti-NECTIN4 ADC Enfortumab vedotin (EV) beyond UC at #ASCO24 ! ASCO

Data of multi-cohort EV-202 (NCT04225117) will be released!
➡️Excited to see the single-agent activity of EV in biomarker-unselected (NECTIN4 status not required!)
- gastric/esophageal cancer

Congratulations to the amazing Scott Kopetz for his AACR Waun Ki Hong Award. Eye opening listening to his presentation on Adaptive Resistance in BRAF- and KRAS-mutated #colorectalcancer #crcsm #AACR24 #AACRSSP MD Anderson Cancer Center

AR-PROTAC BMS-986365 is a potent & rapid AR degrader with enzalutamide-like antagonist potency, low AR agonism, weak activity against AR L702H, claimed to be selective against CRBN neosubstrates (data not shown) & allows to overcome AR feedback up-regulation. #AACR24 #TPD

The #OncoAlertTOPtweet at Day 1 of #EAU24
Post By OncoAlert 🚨GU Faculty Tom Powles 🇬🇧

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and

It‘been a while, but 🎉🔬 The 17th episode is out.
The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥

But what do you know about PD-L1 testing ?
Today Matt Galsky presented important data of CheckMate274 at #EAU24 . PD-L1 positive

So insightful! Never understood it as well until this explanation! Worth reading if you too have been stumped by the lack of consistency of clinical data when you group it together.

This trial will answer several important questions- do we need to escalate therapy to get better outcomes in the highest risk patients, and can we de-escalate in those who are lower risk. Matt Galsky Andrea Apolo, M.D. Tom Powles Guru P. Sonpavde, MD Tian Zhang, MD, MHS

We report for the 1st time therole of tumor fraction in ctDNA in pts w/ mUC in RW Foundation Medicine
👉 ass. w/ clinico-path features & rwPFS
👉prognostic biomarker
👉may help personalize tx
👉prospective trials needed

ESMO - Eur. Oncology Elsevier News Cleveland Clinic MD

protect-us.mimecast.com/s/jGBqCR6nEvtn…

Excellent/elegant work by Ben Miron Shilpa Gupta et al. Agree that ctDNA holds high promise in UC. Its clinical utility regarding decision making needs well-designed trials with relevant endpoints Matt Galsky Hsieh Lab Joshua Meeks Parminder singh Gavin Ha Dr. Bishoy M. Faltas Uromigos

From NYSE: The co-founder of Scion Life Sciences on coming out of stealth mode and the new $310 million venture fund announced this week.

Full video: biotechtv.com/post/scion-lif…

❤️ Love our Fox Chase Cancer Center home team - couldn't ask for a better crew! Some not pictured, others covering back home, many Fox Chase Cancer Center Department of Urology contributions to #GU24

NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 ASCO #GU24 ! Markus Eckstein OncoAlert UroToday.com

Grateful for the unwavering support of my mentors Toni Choueiri, MD and Eli Van Allen
It was a pleasure to present part of our work with Chris Labaki Ziad Bakouny, MD, MSc Ben Miron Matthew Zibelman Elizabeth Plimack MD

Check out our poster # 459 at ASCO #GU24 on Saturday!

Congrats Ben Miron on presenting tumor fraction in ctDNA as a prognostic biomarker in mUC
Ryon Graf, PhD Candice Nulsen Fox Chase Cancer Center Cleveland Clinic MD Elizabeth Plimack MD FoundationOne

Love seeing our Fox Chase Cancer Center crew at #ESMO2023 #ESMO23 ! Hossein Borghaei, DO Ben Miron Namrata (Neena) Vijayvergia MD

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3) #ESMO2023

Tom Powles rocks the stage with practice-changing EV302 trial with impressive OS & PFS benefit with pembro/EV vs chemotherapy! Standing ovation & cheers by 20K people, amazing news for patients! ESMO - Eur. Oncology #esmo23 OncoAlert UroToday.com awaiting Andrea Apolo, M.D. really great discussion

🔥Breaking News at #ESMO2023 !🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302 . Terrific presentation by Tom Powles. 🙌🔬🎗️ UroToday.com OncoAlert ESMO - Eur. Oncology

Sometimes we use this term too loosely but this EV-302 study truly is a GAME CHANGER.